2 news items
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
ONCT
18 Apr 24
in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
ONCT
7 Mar 24
. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact Information
- Prev
- 1
- Next